Cholangiocarcinoma  >>  oxaliplatin  >>  Phase 2
Welcome,         Profile    Billing    Logout  

81 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
2004-001126-24: Feasibility of radiotherapy and concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma

Completed
2
30
Europe
Gemzar, Eloxatin, Powder for infusion*, Gemzar, Eloxatin
University Hospital Ghent
Pancreatic cancer or distal cholangiocarcinoma
 
 
NCT00286013: Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma

Completed
2
24
Europe
Association of gemcitabine, oxaliplatin and radiotherapy
University Hospital, Ghent
Locally Advanced and Unresectable, But Non-metastatic Pancreatic Adenocarcinoma or Cholangiocarcinoma
05/06
07/08
NCT00338988: Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma

Completed
2
44
US
Capecitabine, Xeloda, Oxaliplatin, Eloxatin
M.D. Anderson Cancer Center, Sanofi-Synthelabo
Cancer of the Gallbladder, Cancer of the Biliary Tract
05/09
05/09
NCT00425841: Stereotactic Radiation Therapy and Combination Chemotherapy in Treating Patients Undergoing Surgery for Locally Advanced Pancreatic Cancer

Completed
2
29
Europe
gemcitabine hydrochloride, oxaliplatin, adjuvant therapy, neoadjuvant therapy, hypofractionated radiation therapy, stereotactic radiosurgery
Technische Universität München
Pancreatic Cancer
 
12/09
GemOx-PDT, NCT00713687 / 2008-001560-37: Gemcitabine/Oxaliplatin and Photodynamic Therapy in Cholangiocarcinoma

Withdrawn
2
0
Europe
Gemcitabine, Oxaliplatin, Photodynamic therapy (Photosan®), No other names
Technische Universität München, Münchner Studienzentrum
Cholangiocarcinoma
 
12/11
NCT00552149 / 2007-001200-20: Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin

Checkmark
May 2014 - May 2014: 
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark P2 data - ASCO
More
Completed
2
150
Europe
Gemox, Cetuximab
Gustave Roussy, Cancer Campus, Grand Paris, Merck Serono International SA
Advanced Biliary Cancer
04/12
04/12
NCT00832637: Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers

Terminated
2
33
US
Cisplatin, Platinol®, Erlotinib, Tarceva®, Gemcitabine, Gemzar®
New Mexico Cancer Care Alliance
Hepatocellular Carcinoma, Cholangiocellular Carcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct, Bile Duct Cancer, Periampullary Adenocarcinoma, Gallbladder Cancer, Extrahepatic Bile Duct Cancer
06/13
03/17
NCT01267344: A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
2
122
RoW
gemcitabine, oxaliplatin, Gemmis, Eloxatin, cetuximab, gemcitabine, oxaliplatin, Erbitux@, Eloxatin
National Health Research Institutes, Taiwan, National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Mackay Memorial Hospital, Tri-Service General Hospital, Chang Gung Memorial Hospital, Taichung Veterans General Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University, Kaohsiung Veterans General Hospital.
Cholangiocarcinoma, Adenocarcinoma of Gallbladder
12/13
05/15
NCT01229111: Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers

Terminated
2
14
US
cediranib maleate, AZD2171, Recentin, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU
National Cancer Institute (NCI)
Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Localized Unresectable Adult Primary Liver Cancer, Periampullary Adenocarcinoma, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
03/14
03/14
NCT01572324: Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas

Completed
2
37
RoW
Oxaliplatin, Fluorouracil, Leucovorin, Capecitabine, 1-OHP, Dacotin, Eloxatin, L-OHP;, 5-Fluorouracil,5FU;, Levofolinic acid,Folinic acid.
Peking University
Biliary Tract Cancer
10/15
04/16
2008-002367-14: Kombineret biologisk behandling og kemoterapi til patienter med inoperabelt cholangiocarcinom

 
2
58
Europe
Gemzar, Eloxatin, Xeloda, Vectibix, Gemzar, Eloxatin, Xeloda, Vectibix, Gemzar, Eloxatin, Xeloda, Vectibix
Vejle Sygehus, Växjö Central Hospital
Inoperabelt cholangiocarcinom
 
 
NCT01247337: Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma

Completed
2
56
Europe
Oxaliplatin, capecitabine, gemcitabine, cetuximab, Oxaliplatin, capecitabine, gemcitabine cetuximab
Dorte Nielsen
Cholangiocarcinoma
02/16
02/16
NCT00779454: Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma

Completed
2
72
Europe
Gemcitabine, Oxaliplatin, Capecitabine,, Panitumumab, Gemcitabine, Oxaliplatin, Capecitabine
Vejle Hospital
Cholangiocarcinoma
03/16
03/16
NCT01206049 / 2010-020385-13: Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations

Completed
2
88
Europe
Gemcitabine, Oxaliplatin, Capecitabine, Panitumumab, Bevacizumab
Vejle Hospital
Cholangiocarcinoma
03/16
03/16
2017-002330-23: EVALUATION OF THE EFFICACY AND TOLERANCE OF A CHEMOTHERAPY BY GEMCITABINE AND OXALIPLATIN ADMINISTERED IN THE LIVER, BY THE HEPATIC ARTERY, ON A CHOLANGIOCARCINOME EVALUATION DE L'EFFICACITE ET DE LA TOLERANCE D'UNE CHIMIOTHERAPIE PAR GEMCITABINE ET OXALIPLATINE ADMINISTREE DANS LE FOIE, PAR L'ARTERE HEPATIQUE, SUR UN CHOLANGIOCARCINOME

Ongoing
2
40
Europe
Solution for injection
University hospital of Montpellier, University hospital of Montpellier
The combination of gemcitabine and oxaliplatin intra-arterial as second-line therapy can greatly improve the Objective Response Disorder (ORT) at 4 months L’association de la gemcitabine et de l’oxaliplatine par voie intra-artérielle comme traitement de seconde ligne peut fortement améliorer le Trouble de Réponse Objective (TRO) à 4 mois., The combination of gemcitabine and oxaliplatin intra-arterial as second-line therapy can greatly improve the Objective Response Disorder (ORT) at 4 months L’association de la gemcitabine et de l’oxaliplatine par voie intra-artérielle comme traitement de seconde ligne peut fortement améliorer le Trouble de Réponse Objective (TRO) à 4 mois., Diseases [C] - Cancer [C04]
 
 
NCT02456714: Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma

Completed
2
30
Europe
FOLFIRINOX, Second line treatment
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Cholangiocarcinoma
10/18
12/18
NCT03778593: FOLFIRINOX for 2nd-line Treatment of BTC

Completed
2
34
RoW
5-Fluorouracil, Leucovorin, Irinotecan, Oxaliplatin, 5% dextrose water, 5DW
Dong-A University Hospital
Biliary Tract Cancer
03/19
01/21
NCT02350686: XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy

Unknown status
2
67
RoW
capecitabine, xeloda, oxaliplatin
Samsung Medical Center
Biliary Tract Cancer
12/19
12/20
NCT02836847: Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Unknown status
2
152
RoW
biological test, GEMOX, Cetuximab, Trastuzumab, Gefitinib, Lapatinib, Everolimus, Sorafenib, Crizotinib
Shanghai Jiao Tong University School of Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Ruijin Hospital, RenJi Hospital, Eastern Hepatobiliary Surgery Hospital, Huashan Hospital
Cholangiocarcinoma of the Extrahepatic Bile Duct, Gallbladder Cancer
12/19
12/20
zs-ICC-2019, NCT03951597: Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Active, not recruiting
2
30
RoW
combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001)
Shanghai Zhongshan Hospital
Cholangiocarcinoma, Intrahepatic
01/20
11/21
NCT03486678: SHR-1210 in Combination With GEMOX in Patients With Advanced BTC

Completed
2
38
RoW
SHR-1210+GEMOX
The First Affiliated Hospital with Nanjing Medical University, Jiangsu HengRui Medicine Co., Ltd.
Biliary Tract Cancer, Cholangiocarcinoma
08/20
11/20
NCT03772132: Chemothetapy FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Unknown status
2
100
RoW
mutation and signal pathway activation status analysis Drug: FORFIRINOX
Shanghai Jiao Tong University School of Medicine, Ruijin Hospital, RenJi Hospital, Eastern Hepatobiliary Surgery Hospital, Huashan Hospital
Cholangiocarcinoma of the Extrahepatic Bile Duct, Gallbladder Cancer
12/20
12/21
NCT03768375: Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Unknown status
2
150
RoW
conventional chemotherapy(FORFIRINOX) combined with target agents, conventional chemotherapy(FORFIRINOX)
Shanghai Jiao Tong University School of Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Ruijin Hospital, RenJi Hospital, Eastern Hepatobiliary Surgery Hospital, Huashan Hospital
Cholangiocarcinoma of the Extrahepatic Bile Duct, Gallbladder Cancer
12/20
12/21
NCT04506281: PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Recruiting
2
128
RoW
neoadjuvant treatment
Shanghai Zhongshan Hospital, Xuhui Central Hospital, Shanghai, Minhang Hospital, Fudan University, Shanghai Jinshan Hospital, Shenzhen University General Hospital
Cholangiocarcinoma, Intrahepatic
08/21
08/23
zs-ICC-2020, NCT04361331: Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma

Active, not recruiting
2
60
RoW
Lenvatinib combined with gemox, gemox chemotherapy, Toripalimab combined with lenvatinib
Shanghai Zhongshan Hospital
Cholangiocarcinoma, Intrahepatic
09/21
12/21
NCT04769908: Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis

Recruiting
2
40
RoW
Systemic Chemotherapy, Lenvatinib, Sintilimab
Sun Yat-sen University
ICC
12/21
12/21
NCT04961788: Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma

Recruiting
2
30
RoW
Gemox combimed PD1 antibody
Shanghai Zhongshan Hospital
Intrahepatic Cholangiocarcinoma
12/21
12/22
NCT05036798: Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.

Active, not recruiting
2
30
RoW
Tislelizumab, Lenvatinib, Gemox
Tianjin Medical University Cancer Institute and Hospital
Potentially Resectable Locally Advanced Malignant Tumors of Biliary System
07/22
12/23
QLYY-iCCA-01, NCT06239532: HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Recruiting
2
25
RoW
HAIC+TAE, Tislelizumab, Surufatinib
Qilu Hospital of Shandong University, BeiGene
Intrahepatic Cholangiocarcinoma
05/24
12/25
NCT04523402: Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis

Not yet recruiting
2
100
NA
Neoadjuvant chemotherapy, Preoperative chemotherapy
Eastern Hepatobiliary Surgery Hospital
Intrahepatic Cholangiocarcinoma Recurrent
12/22
12/23
NCT05291052: Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors

Recruiting
2
20
RoW
Tislelizumab, Lenvatinib, Oxaliplatin, Capecitabine
The First Affiliated Hospital with Nanjing Medical University
Biliary Tract Tumor
03/23
03/24
NCT04834674: DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

Recruiting
2
20
RoW
DEB-TACE combined with apatinib and PD-1 antibody
Sichuan Cancer Hospital and Research Institute
Intrahepatic Cholangiocarcinoma, Transarterial Chemoembolization, Apatinib, PD-1 Antibody
04/25
04/26
NCT05290116: HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma

Recruiting
2
17
RoW
HAIC Combined with Tislelizumab and Apatinib
Yunfei Yuan
Intrahepatic Cholangiocarcinoma
05/23
09/23
GWK2023-001, NCT06335927: HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC

Recruiting
2
45
RoW
HAIC-GEMOX+Cadonilimab+Regorafenib
Fudan University
Intrahepatic Cholangiocarcinoma
05/25
05/26
NCT05448183: An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma

Recruiting
2
45
RoW
Toripalimab, Gemcitabine,Oxaliplatin
Xuhua Duan
Extrahepatic Cholangiocarcinoma
05/23
05/24
NCT04217954: HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC

Completed
2
32
RoW
OXA, 5-FU and bevacizumab plus Toripalimab, FOLFOX
Peking University
Advanced Biliary Tract Cancer
05/23
06/23
GEMOXIA-02, NCT03364530: Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma

Recruiting
2
40
Europe
Gemcitabine-Oxaliplatin Regimen, Hepatic intra arterial chemotherapy
University Hospital, Montpellier, Federation Francophone de Cancerologie Digestive
Cholangiocarcinoma Non-resectable, Non-metastatic
06/24
06/25
KCSG-HB19-14, NCT04722133: Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy

Completed
2
36
RoW
HERZUMA+mFOLFOX
Yonsei University
HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer
06/23
06/23
NCT05348811: HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

Recruiting
2
32
RoW
HAIC combined with donafenib and sintilimab, HAIC-donafenib-sintilimab
Zhongda Hospital
Cholangiocarcinoma
06/23
07/23
NCT05620498: Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.

Recruiting
2
60
RoW
tislelizumab+lenvatinib+GMOX, tislelizumab+GEMOX
Tianjin Medical University Cancer Institute and Hospital
Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
06/23
03/24
NCT04984980: Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer

Active, not recruiting
2
37
RoW
Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab
Fudan University
Biliary Tract Carcinoma, Initially Unresectable
07/23
07/23
NCT03603834: Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma

Recruiting
2
25
RoW
mFOLFOXIRI, Oxaliplatin, Irinotecan, Fluorouracil, Leucovorin
Khon Kaen University
Cholangiocarcinoma
08/23
12/23
NCT04191343: Clinical Study on the First-line Treatment of Advanced Biliary System Tumors With Tripley Monoclonal Antibody Combined With GEMOX Regimen

Recruiting
2
20
RoW
Toripalimab injection combined with GEMOX
Zhejiang Cancer Hospital
Advanced Biliary Tract Tumors
09/23
06/24
NCT06134193: Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

Not yet recruiting
2
41
NA
HAIC, Surufatinib, Tislelizumab
Wuhan Union Hospital, China
Carcinoma, Intrahepatic Cholangiocarcinoma, Gallbladder Cancer, Surufatinib, Angiogenesis Inhibitors, Tislelizumab, Antineoplastic Agents, Immunological, Immunotherapy
06/24
06/25
NCT04668976: A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

Recruiting
2
100
US
Medtronic pump and Codman catheter, Floxuridine (FUDR), Gemcitabine, Oxaliplatin, Irinotecan (CPT-11), Fluorouracil, Anti-EGFR (Panitumumab or Cetuximab)
Benaroya Research Institute, Virginia Mason Hospital/Medical Center
Colorectal Cancer, Cholangiocarcinoma
12/23
12/24
NCT05024513: Biliary Drainage Plus HAIC in Locally Advanced pCCA

Recruiting
2
127
RoW
oxaliplatin and 5-fluorouracil, Biliary Drainage, Best Supportive Care, External biliary drainage
Peking University
Perihilar Cholangiocarcinoma
12/24
12/25
NCT05935579: Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Recruiting
2
40
RoW
Durvalumab, Lenvatinib Oral Product, Chemotherapy
Peking Union Medical College Hospital
Biliary Tract Neoplasms, Immunotherapy
12/23
12/24
NCT03406299: Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer

Active, not recruiting
2
92
RoW
Tegafur, S-1, Leucovorin, Folinic acid, Oxaliplatin, oxalic, Gemcitabine, Gemmis, Cisplatin
National Health Research Institutes, Taiwan
Biliary Tract Neoplasms
12/23
12/23
NCT05400902: HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma

Recruiting
2
17
RoW
HAIC Combined with Tislelizumab and Apatinib
Binkui Li
Intrahepatic Cholangiocarcinoma
12/23
12/23
NCT05251662: Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma

Recruiting
2
90
RoW
Sintilimab, IBI305, Bevacizumab Biosimilar, GEMOX
Tianjin Medical University Cancer Institute and Hospital
Intrahepatic Cholangiocarcinoma
01/24
01/25
NCT05430698: PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma

Recruiting
2
62
RoW
PD-1antibody plus GEMOX
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Perihilar Cholangiocarcinoma
01/24
10/25
NCT04505553: Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer

Active, not recruiting
2
77
US
Acupuncture Therapy, Acupuncture, Acupressure Therapy, acupressure, Ischemic Compression, Oral Cryotherapy, Questionnaire Administration, Quality-of-Life Assessment, Quality of Life Assessment
University of Washington, National Cancer Institute (NCI), The Safeway Foundation
Appendix Carcinoma, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Malignant Digestive System Neoplasm, Pancreatic Carcinoma, Rectal Carcinoma, Small Intestinal Carcinoma, Anal Carcinoma, Digestive System Carcinoma, Digestive System Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor
03/24
09/24
NCT06208462: Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Recruiting
2
33
RoW
Adebrelimab, SHR-1316, Lenvatinib, 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide, Gemcitabine, Difluorodeoxycytidine Hydrochloride, Oxaliplatin, Diaminocyclohexane Oxalatoplatinum
The First Affiliated Hospital with Nanjing Medical University, Jiangsu Hengrui Pharmaceutical Co., Ltd.
Intrahepatic Cholangiocarcinoma
01/26
01/27
NCT04931420: Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels

Not yet recruiting
2
48
NA
Standard of Care Chemotherapy, Video-Assisted Thoracic Surgery (VATS), thoracoscopy, thoracoscopic surgery or pleuroscopy,, Lobectomy, Consolidative Radiation, intensification therapy, postremission therapy., Ablation Treatment, Resection or Excision, Peritonectomy, Transarterial Radioembolization, TARE
University of Chicago
Metastatic Cancer, Foregut Carcinoid Tumor, Gastric Adenocarcinoma, Gallbladder Adenocarcinoma, Liver Cancer, GI Cancer, GI Carcinoma, Lung Cancer
05/26
11/27
CCGLC-013, NCT06192797: Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

Recruiting
2
36
RoW
HAIC, hepatic arterial infusion chemotherapy of GEMOX, Lenvatinib plus pucotenlimab, levima plus pucotenlimab
Ze-yang Ding, MD, Geneplus-Beijing Co. Ltd., Chinese Cooperative Group of Liver Cancer
Cholangiocarcinoma Non-resectable
12/25
06/26
HELIX-ICC, NCT04251715: mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

Active, not recruiting
2
5
US
Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Floxuridine, 2''-Deoxy-5-fluorouridine, 5-Fluoro-2''-deoxyuridine, 5-Fluorodeoxyuridine, 5-Fluorouracil deoxyriboside, 5-FUdR, FDUR, Floxuridin, Fluorodeoxyuridine, Fluorouridine Deoxyribose, Fluoruridine Deoxyribose, FUdR, WR-138720, Implanted Medical Device, IMPLANTED, Irinotecan, Leucovorin, Folinic acid, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Quality-of-Life Assessment, Quality of Life Assessment
OHSU Knight Cancer Institute, Oregon Health and Science University
Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Intrahepatic Cholangiocarcinoma
06/24
11/24
NCT03693807: A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

Active, not recruiting
2
35
US
Medtronic pump and Codman catheter, Floxuridine (FUDR), Gemcitabine, Oxaliplatin, Irinotecan (CPT-11), Fluorouracil, Anti-EGFR (Panitumumab or Cetuximab)
Memorial Sloan Kettering Cancer Center
Colorectal Cancer, Cholangiocarcinoma
09/24
09/24
NCT05668884: GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma

Recruiting
2
35
RoW
Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab
Fudan University
Biliary Tract Carcinoma
09/24
03/25
GOT, NCT05557578: Applied as Neoadjuvant Regimen for Patients of Resectable ICC With High-risk Factors of Recurrence

Recruiting
2
20
RoW
Tislelizumab combined with GEMOX (GOT) regimen, Gemcitabine, Oxaliplatin
Zhejiang Cancer Hospital
Intrahepatic Cholangiocarcinoma
10/24
12/24
ChiCTR2200065621: A phase II study of camrelizumab plus gemcitabine and oxaliplatin followed by camrelizumab and fluzoparib or apatinib in first-line treatment for advanced or metastatic biliary tract carcinoma

Not yet recruiting
2
62
 
Camrelizumab(200mg,d1)+gemcitabine(800mg/m2,d1,d8)+oxaliplatin(100mg/m2,d1),Q3W,4-6 cycles, followed by camrelizumab(200mg,d1,Q3W)+fluzooparib(150mg,bid), up to 2 years ;Camrelizumab(200mg,d1)+gemcitabine(800mg/m2,d1,d8)+oxaliplatin(100mg/m2,d1),Q3W,4-6 cycles, followed by camrelizumab(200mg,d1,Q3W)+apatinib(250mg,qd), up to 2 years
Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, NA
biliary tract carcinoma
 
 
NCT05864755: HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma

Recruiting
2
30
RoW
HAIC+Durvalumab+Tremelimumab+Bevacizumab
Tianjin Medical University Cancer Institute and Hospital
Unrescetable Hepatocellular Carcinoma
12/24
12/25
ComboMATCH Treatment Trial, NCT05564403: Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A )

Recruiting
2
66
US
Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669
National Cancer Institute (NCI)
Recurrent Biliary Tract Carcinoma, Recurrent Distal Bile Duct Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Biliary Tract Carcinoma, Unresectable Distal Bile Duct Adenocarcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
01/25
01/25
ChiCTR2200056808: Terelizumab combined with lenvatinib and GEMOX (gemcitabine plus oxaliplatin) as conversion therapy for unresectable extrahepatic biliary carcinoma

Not yet recruiting
2
48
 
Terelizumab combined with lenvatinib and GEMOX (gemcitabine + oxaliplatin)
The First Medical Center of the People's Liberation Army General Hospital; The First Medical Center of the People's Liberation Army General Hospital, Self-raised
Unresectable extrahepatic biliary carcinoma
 
 
NCT01862315: Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)

Active, not recruiting
2
55
US
Floxuridine (FUDR), dexamethasone, Gemcitabine, Oxaliplatin, MRI, Research blood draws
Memorial Sloan Kettering Cancer Center
Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma, Cholangiolar Carcinoma, Cholangiocellular Carcinoma
05/25
05/25
NCT04891289: Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

Recruiting
2
164
US
Gemcitabine, Oxaliplatin, Dexamethasone, Floxuridine (FUDR), Implanted Medical Device
Memorial Sloan Kettering Cancer Center
Intrahepatic Cholangiocarcinoma
05/25
05/25
ZWI-ZW25-201, NCT03929666: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Active, not recruiting
2
74
Canada, US, RoW
ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine
Jazz Pharmaceuticals
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
11/25
10/26
BOLSTER, NCT05712356: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

Recruiting
2
80
Europe, US
LSTA1, Durvalumab, Cisplatin, Gemcitabine, FOLFOX regimen, Oxaliplatin, Folinic acid, Fluorouracil, Placebo
Lisata Therapeutics, Inc.
Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma
12/25
12/25
PAMICC, NCT04796454: Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer

Withdrawn
2
0
NA
Cisplatin, Gemcitabine, Oxaliplatin, Pamiparib, Temozolomide
European Organisation for Research and Treatment of Cancer - EORTC
Platinum-Sensitive Biliary Tract Cancer
07/26
08/26
HERCKER-01, NCT05985707: KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

Not yet recruiting
2
80
RoW
KN026, KN046, XELOX
Peking University Cancer Hospital & Institute
HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer
12/26
12/26
KEYVIBE-005, NCT05007106 / 2021-001009-56: MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005)

Recruiting
2
610
Europe, Canada, Japan, US, RoW
Pembrolizumab/Vibostolimab Co-Formulation, MK-7684A, Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, Lenvima, E7080, MK-7902, 5-Fluorouracil, 5-FU, Fluracil, Cisplatin, Platinol, cis Platinum, Paclitaxel, Taxol, Abraxane, Anzatax, Gemcitabine, Carboplatin, Docetaxel, Bevacizumab, Capecitabine, Oxaliplatin
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC
Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Triple Negative Breast Neoplasms, Hepatocellular Carcinoma, Urinary Bladder Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
02/27
02/27
NCT05286814: M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma

Recruiting
2
48
US
Floxuridine, 5-Fluorouracil, Irinotecan, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Oxaliplatin, Leucovorin, M9241, Gemcitabine, Dexamethasone
National Cancer Institute (NCI)
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Colorectal Cancer, Colorectal Neoplasms, Cholangiocarcinoma, Intrahepatic Bile Duct Cancer, Bile Duct Cancer, Bile Duct Neoplasms
12/27
12/28
NCT00350961: Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma

Completed
1/2
39
Europe
Gemcitabine, Oxaliplatin, Capecitabine
Rigshospitalet, Denmark, Henrik Jensen, Dept. of Oncology, Vejle Sygehus, Vejle, Denmark
Cholangiocarcinoma
 
02/08
2013-004385-34: Activity of Regorafenib in combination with modified Gemcitabine - Oxaliplatin Chemotherapy (mGEMOX) in patients with advanced Biliary Tract Cancer (BTC): A Phase Ib-II trial

Not yet recruiting
1/2
87
Europe
Coated tablet, Powder for solution for infusion, STIVARGA, GEMCITABINE, OXALIPLATINE
Institut régional du Cancer - Montpellier - Val d'Aurelle, Institut régional du Cancer - Montpellier - Val d'Aurelle
advanced Biliary Tract Cancer, Biliary Cancer, Diseases [C] - Cancer [C04]
 
 
NCT00955721: A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer

Terminated
1/2
9
US
Gemcitabine, Gemzar, Oxaliplatin, Eloxatin, Sorafenib, BAY 43-9006
University of Miami
Cholangiocarcinoma, Biliary Tract Cancer, Gallbladder Cancer
07/14
07/14
NCT02024607: A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark ASCO-GI
Jan 2016 - Jan 2016: ASCO-GI
Checkmark ASCO-GI 2016
More
Completed
1/2
495
Canada, US
BBI608, Napabucasin, BB608, BBI-608, Fluorouracil, 5-FU, Carac, Efudex, Fluoroplex, Adrucil, Oxaliplatin, Eloxatin, Leucovorin, Folinic Acid, Irinotecan, Camptosar, Bevacizumab, Avastin, Capecitabine, Xeloda, Regorafenib, Stivarga
Sumitomo Pharma America, Inc.
Advanced Gastrointestinal Cancer
03/19
11/19
NCT03943043 / 2016-004118-84: Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer

Unknown status
1/2
85
Europe
nab-paclitaxel, Gemcitabine, Oxaliplatin
Istituto Clinico Humanitas
Cholangiocarcinoma
09/20
05/21
NCT05116891: A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors

Completed
1/2
40
Europe
CAN04 (nadunolimab), nadumolimab, mFOLFOX, Modified Folfox; Oxaliplatin, 5-fluorouracil (5-FU), leucovorin, DTX, Docetaxel, G/C, Gemcitabine and cisplatin
Cantargia AB
Advanced Solid Tumors, Colorectal Cancer, Non Small Cell Lung Cancer, Biliary Tract Cancer
06/23
06/23
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Recruiting
1/2
320
RoW
TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab
Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb
Advanced Cancer
08/24
11/24
SGNTUC 024, NCT04430738: Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Recruiting
1/2
40
Japan, US
tucatinib, TUKYSA, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab, KEYTRUDA
Seagen Inc.
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
03/25
10/25
NCT06033118: Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC

Not yet recruiting
1/2
25
NA
gemcitabine ,oxaliplatin,anlotinib,Sintilimab
Sichuan University
Combined Hepatocellular Cholangiocarcinoma
07/25
08/26
NCT05849480: A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Recruiting
1/2
60
US
oxaliplatin, capecitabine, Keytruda, CDX-1140
National Cancer Institute (NCI)
Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct
06/40
06/42

Download Options